Citi analyst Joel Beatty reiterated his Buy rating and $200.00 price target on Madrigal Pharmaceuticals (NASDAQ: MDGL) while raising EPS ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE